![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » AveXis to Manufacture Mass General’s COVID-19 Vaccine
AveXis to Manufacture Mass General’s COVID-19 Vaccine
![AveXis logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/AveXis-Logo.gif?t=1590702176&width=430)
May 29, 2020
Novartis-subsidiary AveXis has entered into an agreement to manufacture a COVID-19 vaccine being developed by Massachusetts General Hospital and Massachusetts Eye and Ear.
AveXis will supply the gene-therapy vaccine at no cost for COVID-19 trials scheduled to begin in the second half of 2020 and will expand production if the candidate is successful.
The AveXis agreement signals Novartis’ re-entry into the vaccine market. The company sold off its vaccine business to GlaxoSmithKline in 2015.
Upcoming Events
-
21Oct